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Background: The efficacy of the 8-aminoquinoline (8AQ) drug primaquine (PQ) has been historically linked to
CYP-mediated metabolism. Although to date no clear evidence exists in the literature that unambiguously assigns
the metabolic pathway or specific metabolites necessary for activity, recent literature suggests a role for CYP 2D6 in
the generation of redox active metabolites.
Methods: In the present study, the specific CYP 2D6 inhibitor paroxetine was used to assess its effects on the
production of specific phenolic metabolites thought to be involved in PQ efficacy. Further, PQ causal prophylactic
(developing liver stage) efficacy against Plasmodium berghei in CYP 2D knockout mice was assessed in comparison
with a normal C57 background and with humanized CYP 2D6 mice to determine the direct effects of CYP 2D6
metabolism on PQ activity.
Results: PQ exhibited no activity at 20 or 40 mg/kg in CYP 2D knockout mice, compared to 5/5 cures in normal
mice at 20 mg/kg. The activity against developing liver stages was partially restored in humanized CYP 2D6 mice.
Conclusions: These results unambiguously demonstrate that metabolism of PQ by CYP 2D6 is essential for anti-
malarial causal prophylaxis efficacy.Background
The 8-aminoquinoline anti-malarial drug primaquine (PQ)
is of seminal importance in the fight against malaria, as it is
the only drug currently indicated to treat relapsing strains of
Plasmodium vivax and Plasmodium ovale (antihypnozoite
activity). Due to its antihypnozoite in P. vivax and
gametocytocidal activity in P. falciparum, it is often consid-
ered in strategies for mass administration with the goal of
malaria elimination [1].
PQ efficacy is thought to be dependent upon biotrans-
formation, but the essential pathways for this activation
have, to date, not been reported [2,3]. PQ is known to inter-
act with several CYP enzymes as well as monoamine oxi-
dases (MAOs) [4-7]. Constantino et al. [4] demonstrated
that the role of MAOs was most likely in the catalysis of the
first step (deamination to the aldehyde) on the pathway to
carboxyprimaquine, the major plasma metabolite of PQ.* Correspondence: brandon.pybus@us.army.mil
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reproduction in any medium, provided the orCarboxyprimaquine has been shown to lack efficacy or tox-
icity [4]. However, the most likely mechanism of action for
PQ is one mediated by the formation of reactive oxygen spe-
cies through redox cycling of hydroxylated metabolites and
subsequent toxicity to the parasite [2,7,8]. It was recently
demonstrated that hydroxy metabolites of PQ are predom-
inantly generated via metabolism by CYP 2D6 [6]. CYP 2D6
is subject to highly polymorphic genetic variability, which af-
fects the pharmacokinetics of roughly 50% of the drugs on
the market [9]. If PQ efficacy is solely dependent upon CYP
2D6 metabolism, this could present a serious problem for
eradication efforts centred around PQ use, as many popula-
tions throughout the world (including endemic areas) have
high prevalence of allelic frequency for poor and intermedi-
ate activity CYP 2D6 [10]. As an example, Bennett et al. re-
cently reported two clinical PQ failures in a P. vivax
challenge which were linked to subjects of the poor and
intermediate CYP 2D6 genotype (personal communication
by Bennett et al.). The recent development of a murine
model of CYP 2D6 polymorphism has made it feasible to
address the question of whether PQ efficacy has anytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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strains in which the CYP 2D cluster is deleted and can be
replaced with allelic variants of human CYP 2D6 [11]. In
the present study, this model was used to determine if ma-
nipulation of CYP 2D mediated metabolic pathways of PQ
in mice has direct effects on causal prophylactic anti-
malarial efficacy. Specifically, PQ efficacy was compared in
strains of mice, which would model either the CYP 2D6
null/poor metabolizer variant or the extensive metabolizer.
Further, the effects of the potent CYP 2D6 inhibitor paroxe-
tine (PXT) were demonstrated on the in vitro production by
human recombinant CYP 2D6 of the phenolic metabolites
thought responsible for PQ activity.
Methods
Chemicals used
Chemicals used were: primaquine (Sigma, St Louis, MO,
USA, #160393), paroxetine (Sigma, #P9623), nicotina-
mide adenine dinucleotide phosphate, oxidized form
(NADP) (Sigma, # 077 K7000), acetonitrile (Fisher
Scientific, Waltham, MA, USA, #972970), glucose-6-
phosphate (G6P) (Sigma, # 046 K3779), glucose-6-
phosphate dehydrogenase (G6PD) (Sigma, # 068 K3795),
and magnesium chloride (MgCl2) (Sigma, #102 K0154).
Mobile phases were made with HPLC grade water, aceto-
nitrile and formic acid.
CYP2D6 incubations
In vitro metabolism studies with the CYP2D6 isoenzyme
were conducted according to the manufacturer’s instruc-
tions (BD Gentest, San Jose, CA, USA). Briefly, the pro-
cedure was as follows: a 30 μl aliquot of 5 mg/ml
CYP2D6 was mixed with the NADPH regeneration sys-
tem A (50 μl) and B (10 μl), and 990 ml of phosphate
buffer (pH 7.4, 100 mM) was added. The solution was
mixed gently by pipetting and incubated at 37°C for
2 min. Primaquine (10 μM final concentration) was
added in the absence or presence of various concentra-
tions of the CYP2D6 inhibitor paroxetine (0, 5, 10, 15,
50 μM). A portion of the mixture (120 μl) was then col-
lected at several time points (0, 60 min) followed by
quenching with an equal volume of acetonitrile. The
samples were vortexed for 30 sec, and centrifuged at
13,200 × rpm at 4°C for 10 min. The supernatant was
collected and loaded onto 96-well plates (200 μl/well)
for LC-MS analysis.
Primaquine metabolite identification
Primaquine samples were analysed using a Waters
(Milford, MA, USA) Acquity UPLC system coupled to a
Xevo Q-ToF mass spectrometer equipped with a stand-
ard electrospray ionization source. Chromatographic
separations were achieved using a Waters Acquity BEH
C18 1.7 μm 2.1 mm × 100 mm column with a 2 to 98%acetonitrile gradient over 6.10 min at a flow rate of
0.70 mL/min. Mobile phase A consisted of 10 mM am-
monium bicarbonate and mobile phase B consisted of
acetonitrile. The gradient consisted of phase B increasing
from 2 to 60% in the time period of 0 to 2.9 min,
followed by 60 to 98% from 2.9 to 4.7 min, holding at
98% B from 4.7 to 5.2 min, and then returning to 2% B
from 5.2 to 6.1 min. MS conditions were optimized for
primaquine detection in the positive electrospray mode
with the corresponding instrumental parameters: capil-
lary 1 kV, sampling cone 20 V, extraction cone 4 V,
source temperature 120°C, desolvation temperature 150°C,
cone gas flow 30 L/Hr, and desolvation gas flow 600 L/Hr.
Low energy MS scans were conducted using a collision
energy of 6 V. Primaquine fragments were produced using
the MSE mode with a collision energy ramp from 15–
18 V. Primaquine metabolites were indentified and
analysed using Waters Metabolynx software, MSE and
MS/MS analysis.IVIS study for C57BL/6 and knockout mice
PQ was administered orally on days −1, 0, and 1 with re-
spect to sporozoite inoculation. At 24, 48, and 72 hours
post-sporozoite infection, all inoculated mice were tested
using the Caliper Life Sciences (Hopkinton, MA, USA)
IVIS Spectrum instrument. Additionally, emerging blood
stage infections were measured by a flow cytometry sys-
tem (FC500 MPL, Beckman Coulter, Miami, FL, USA).
Positive and negative controls are routinely used for the
IVIS calibration in each test.Sporozoites, inoculation and viability check
Plasmodium berghei sporozoites (luciferase expressing)
were obtained from laboratory-reared female Anopheles
stephensi mosquitoes from Department of Mosquito
Biology, WRAIR and maintained at 18°C for 17 to
22 days after feeding on malaria infected Swiss CD-1/
ICR mice. Salivary glands were extracted from malaria-
infected mosquitoes and sporozoites were recovered by
using in house procedures. Briefly, mosquitoes were sep-
arated into abdomen and head/thorax. Heads and thor-
axes were triturated with a mortar and pestle and
suspended in medium RPMI 1640 containing 1%
C57BL/6 mouse serum (Rockland Co., Gilbertsville, PA,
USA). A total of 50–80 heads with glands were placed
into a 0.5 ml Osaki tube on top of glass wool with
enough dissection media to cover the heads. The Osaki
tube was kept on ice until all mosquitoes had been dis-
sected. Sporozoites isolated from the same batch of mos-
quitoes were inoculated into C57BL/6, 2DKO and
2DKO/KI C57BL/6 mice on the same day to control for
biological variability in sporozoite preparations. Each
mouse was inoculated intravenously in the tail vein with
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volume on day 0.
To ensure that inoculated sporozoites were viable fol-
lowing the isolation procedure, they were stained with a
vital dye containing fluorescein diacetate (50 mg/ml in
acetone) and ethidium bromide (20 μg/ml in phosphate-
buffered saline; Sigma Chemical Co., St Louis, MO,
USA) and counted in a haemocytometer. The viability of
sporozoites ranged from 90 to 100%.
Animals
Male eight-week-old C57BL/6, 2DKO and 2DKO/KI
mice (Taconic, Hudson, NY, USA) were used. On arrival,
the animals were acclimated for seven days (quarantine).
The animals were housed in a cage maintained in a
room with a temperature range of 18-26°C [express
in °C], 34-68% relative humidity and a 12-hr light/dark
cycles. Food and water were provided ad lib during
quarantine and throughout the study. The animals were
fed a standard rodent maintenance diet. All animal stud-
ies were performed under IACUC approved protocols.
All animal use, care and handling were performed in ac-
cordance with the current Guide for the Care and Use
of Laboratory Animals (1996).
Test agents and administration
The compounds tested in these experiments were dosed
based on the body weight at the time of preparation of
the suspension solution. The suspension solution of oral
agents were prepared in 0.5% (w/v) hydroxyethyl cellu-
lose and 0.2% (0.5% HECT, v/v) Tween-80 in distilled
water, using homogenizer (PRO Scientific Inc, Monroe,
CT, USA) with 10 mm open slotted generator to
homogenize drug powder mixture at 20,000-22,000 rpm
for 5 min in ice bath. A once-a-day, three-consecutive-
day treatment regimen (−1, 0, 1 day) was used in
all assessments. This volume was transferred to a
20-ml bottle, drawn into a 1-ml syringe, and deli-
vered via intragastric feeder (18-gauge) to the desig-
nated recipient.
IVIS spectrum
In vivo imaging of luciferase activity from luciferase ex-
pressing P. berghei-infected mice was performed using a
Xenogen IVIS-200 Spectrum (Caliper Life Sciences,
Hopkinton, MA, USA) in vivo imaging system. Mice
were evaluated at 24, 48 and 72 hours post-sporozoite
inoculation to determine liver- and blood-stage malaria
infection. D-Luciferin potassium salt, (Xenogen, California
and Goldbio, St Louis, MO, USA), the luciferase substrate,
was intraperitoneally inoculated into mice at a concentration
of 200 mg/kg 15 min before bioluminescence analysis. The
mice were anaesthetized with isoflurane 3 min post-luciferin
administration. The mice were then positioned ventral sideup in the IVIS on the 37°C platform. The mice continued to
receive isoflurane through the nose-cone delivery. The cam-
era exposure time was 5 min for the 24, 48 and 72-hr time
points with f-stop = 1 and large binning setting. Photons
emitted from specific regions were quantified using Living
Image® 3.0 software and total ROI was calculated. 3-D bio-
luminescent imaging tomography was performed with Liv-
ing Image 3.0 software using sequential images taken with
filters ranging from 580 to 660 nm.
Results
CYP2D6-mediated hydroxylation of primaquine
In order to understand the role of CYP 2D6 in the bio-
transformation and bio-activation of primaquine, several
experiments were conducted with primaquine and re-
combinant CYP2D6. Primaquine was incubated with
CYP2D6 for 60 min with all necessary cofactors needed
for CYP 2D6 activity. Incubations were then quenched
with acetonitrile and the resulting metabolites formed
were analysed by UPLC-MS analysis. The most abun-
dant ions detected using the described experimental
conditions were that of primaquine and a +16 Da modi-
fied metabolite. The corresponding MSE spectra for
primaquine and the metabolite are shown in Figures 1A
and B respectively. Figure 1A shows the predominant
fragment ions of primaquine and their corresponding m/z
values. These fragments comprise the entire primaquine
molecule including fragments of the quinoline core and the
8-amino side chain. The fragmentation pattern of the
primaquine metabolite is shown in panel B. Frag-
ments with +16 Da mass shifts were observed upon
MSE fragmentation and are highlighted in red. These
fragments corresponded to the quinolone core of
primaquine (191.10 and 259.16m/z) and indicate that
CYP 2D6 produces phenolic metabolites in vitro.
To further probe the CYP 2D6-mediated metabolism
of primaquine, the CYP 2D6 inhibitor paroxetine was
utilized to determine if inhibition of the enzyme would
prevent phenolic metabolite formation. Primaquine was
incubated with CYP 2D6 in the absence or presence of
varying concentrations of paroxetine. The relative %
primaquine and the phenolic metabolite present were
determined for each paroxetine incubation. The results
for the paroxetine incubations are shown in Figure 2.
Panel A shows the relative % primaquine remaining after
60 min with CYP 2D6. Under these conditions, prima-
quine was rapidly metabolized by CYP 2D6 in the ab-
sence of paroxetine, as less than 20% remained after
60 min. CYP 2D6-mediated metabolism of primaquine
was significantly decreased upon incubation with in-
creasing concentrations of paroxetine. In addition to
monitoring primaquine parent loss, the formation of the
phenolic metabolite described above was also monitored.
Panel B shows the disappearance of this phenolic
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Figure 1 CYP2D6-mediated hydroxylation of primaquine.
A. Shown is the MSE fragmentation spectrum for primaquine. The
(M + 1) charge state of primaquine is highlighted in blue. The major
fragment ions of primaquine produced upon MSE fragmentation are
also shown along with their corresponding m/z values and
structures. B. MSE fragmentation of hydroxylated primaquine.
Fragment ions utilized for localization of the hydroxylation to the
quinoline core are indicated in red. It should be noted that MSE
fragmentation localizes this transformation to the quinoline core,




























































Figure 2 Primaquine metabolism with paroxetine inhibition of
CYP2D6. A. Shown is the relative % primaquine remaining after
60-min incubations with CYP2D6 in the absence or presence of
varying concentrations of paroxetine. B. Relative % hydroxylated
metabolite present remaining after 60-min incubations with CYP2D6
in the absence or presence of varying concentrations of paroxetine.
The structures of primaquine and the tentative hydroxylated
metabolite are shown in each corresponding panel. Error bars were
calculated from average values obtained from duplicate analyses.
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centrations. These results indicate that CYP2D6 is im-
portant in the biotransformation of primaquine in vitro
and that inhibiting the enzyme prevents formation of
phenolic primaquine metabolites.
Primaquine efficacy in CYP 2D knockout mice
In order to assess the effects of CYP 2D metabolism on
PQ efficacy, PQ was tested at its ED100 (20 mg/kg ×
3 day PO) in C57BL/6 mice infected with luciferase ex-
pressing P. berghei. Of the five mice inoculated with spo-
rozoites, none exhibited liver stage parasite signal out to
72 hr as compared with vehicle control (Figure 3). The
same dose (20 mg/kg × 3 day PO) in mice containing a
deletion of all nine mouse CYP 2D genes, including CYP
2D22 (the nearest murine ortholog to CYP 2D6) resulted
in no cures. In addition to chemical inhibitors such as
PXT to achieve diminished CYP 2D activity, knockout
mice are presented here due to the poor specificity of
chemical inhibitors in vivo. In order to determine
whether this effect could be overcome via metabolic
switching at higher doses, PQ was tested again at40 mg/kg in the knockout mice, resulting in no cures
(data not shown). Due to the uncertainty in the com-
pleteness of overlap between the activities of mouse
CYP 2D22 and human 2D6, a humanized strain of mice
in which the mouse 2D cluster has been removed and
replaced with human 2D6 was inoculated with P. berghei
sporozoites and treated with 20 mg/kg of PQ. In these
animals, three of five mice had no detectable parasite
burden in the liver at 72 hr as compared with vehicle
control with a mean suppression of 99.3% (Figure 3). Ul-
timately, blood stage infections did appear in all five
animals by day 8 post-inoculation, indicating incomplete
inhibition of parasite growth. Figure 4 shows parasite bur-













Figure 3 Dissemination of malaria parasites by IVIS imaging of C57BL/6 Wild-type (WT), CYP 2D knockout, and humanized CYP 2D
knockout/CYP 2D6 knock-in mice at 24-hr and 72-hr post-inoculation with luciferase expressing Plasmodium berghei. WT animals treated
with 20 mg/kg x 3 days of oral PQ exhibited no parasitaemia at 24 or 72 hr. All five CYP 2D knockout mice exhibited liver stage parasitaemia at
24 hr which progressed to systemic infection by 72 hr. PQ efficacy was largely restored in mice in which the deleted CYP 2D cluster was replaced
with human CYP 2D6.
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post-inoculation.
Discussion
PQ therapy is a key component in the global fight
against malaria, as it is the only approved drug indicated
in the treatment of infections with species that show re-
lapsing infections. As such it remains the standard of
care for radical cure of P. vivax and P. ovale [12]. GivenFigure 4 Parasite dissemination by IVIS imaging of C57BL/6
WT, CYP 2D knockout, and humanized CYP 2D knockout/CYP
2D6 knock-in mice at 24-hr and 72-hr post-inoculation with
luciferase expressing Plasmodium berghei.its gametocytocidal activity against stage 5 Plasmodium
falciparum gametocytes, it is often considered in strat-
egies for transmission blocking and malaria elimination
[1,13,14]. Although not thoroughly understood, PQ effi-
cacy is suspected to be linked to biotransformation via a
CYP dependent pathway leading to the production of
redox cycling metabolites [2,3,6,15]. Phenolic metabo-
lites of PQ are the most likely candidates for such activ-
ity, and have frequently been linked to the associated
haemolytic anaemia observed in G6PD-deficient individ-
uals after PQ therapy [8,16-21]. Given the reactive na-
ture of these metabolites and their demonstrated ability
to redox cycle, they should be considered of potential
importance to any mechanism of action dependent on
the production of oxidative stress. It was recently dem-
onstrated that these phenolic metabolites are predomin-
antly generated via a CYP 2D6 dependent pathway [6].
Although CYP 2D6 is involved in the metabolism of
25% of all drugs on the market, it is known to be highly
polymorphic, with more than 100 allelic variants
reported [11,22,23]. Importantly, Bennett et al. reported
two PQ failures in a P. vivax challenge which could be
directly linked to two of these variants with diminished
activity against hypnozoites, or the sleeping liver stages
(submitted, New England Journal of Medicine). In the
present study, efficacy of primaquine was assessed in a
model of causal malaria prophylaxis (developing liver
stages). The effect observed by Bennett et al. in this
prophylaxis model using mice deficient in CYP 2D poly-
morphism was reproduced. In these animals, the 2D
cluster is deleted, and can be replaced with a variant of
human CYP 2D6 [11]. For the purposes of the present
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the C57BL/6 background versus 2D knockout and hu-
manized knockout knock-in. In this experiment, deletion
of the CYP 2D cluster resulted in all five mice failing PQ
therapy at the ED100 (20 mg/kg × 3 days PO) as deter-
mined in wild-type mice (Figure 3). Further, even twice
the dose resulted in no cures in these animals (data not
shown), suggesting that metabolites generated via 2D
mediated pathways are unlikely to be produced by any
other CYP through metabolic switching. This activity
could, however, be partially restored by the introduction
of human CYP 2D6 in the CYP 2D knockout/human
CYP 2D6 knockin mice (Figure 3). In these animals,
three of five showed no parasitaemia in 72 hr post-
inoculation with an overall 99.3% mean suppression as
compared to vehicle control. Ultimately all five animals
presented with blood stage infections at day 8 post-
infection. This could be due to the somewhat diminished
activity of human CYP 2D6 in this model as compared
to its mouse orthologue CYP 2D22, as Scheer et al.
showed only about a 53% recovery of bufuralol 1’-hy-
droxylase activity in microsomes generated from livers
of the humanized animals versus those from the wild-
type [11]. This may well stem from intrinsic differences
in activity toward common substrates between the two
orthologues, and is not altogether surprising.
Here, presented are in vitro experiments that clearly
demonstrate the effects of diminished CYP 2D6 activity
on PQ metabolism. It was observed that the CYP 2D6
inhibitor paroxetine (PXT) inhibits parent loss of PQ
when incubated with recombinant human CYP 2D6 in a
dose-dependent manner. More importantly, it was also
shown that the generation of phenolic metabolites (the
major products of the metabolism of PQ by CYP 2D6),
as illustrated in Figure 2, is also inhibited in a dose-
dependent manner by PXT. It is important to note, that
the P. berghei model utilized here contains no
hypnozoites, and direct observations of PQ efficacy are
only against primary developing liver stages. This activity
is not necessarily related to PQ’s anti-hypnozoite activity,
however PQ’s oxidative killing mechanism makes it
likely that efficacy against all stages of the parasite are
dependent on activation by metabolism. Taken into con-
text with the murine data here reported, it is reasonable
to conclude that: 1) PQ’s causal prophylactic anti-
malarial efficacy is dependent on biotransformation by
CYP 2D6; 2) phenolic metabolites generated by CYP
2D6 are responsible for this efficacy; and, 3) PQ causal
prophylaxis will be impaired in patients with CYP 2D6
allelic variants of the poor and perhaps also the inter-
mediate metabolizer type.
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